Kraus, Christoph http://orcid.org/0000-0002-7144-2282
Vanicek, Thomas
Weidenauer, Ana
Khanaqa, Tav
Stamenkovic, Mara
Lanzenberger, Rupert http://orcid.org/0000-0003-4641-9539
Willeit, Matthäus
Kasper, Siegfried http://orcid.org/0000-0001-8278-191X
Funding for this research was provided by:
Medical University of Vienna
Article History
Received: 23 January 2018
Accepted: 19 March 2018
First Online: 18 April 2018
Compliance with ethical guidelines
:
: The following statements do not relate to any aspects of the current report. S. Kasper received grants/research support, consulting fees and/or honoraria within the last three years from Angelini, AstraZeneca, Eli Lilly, Janssen, KRKA-Pharma, Lundbeck, Neuraxpharm, Pfizer, Pierre Fabre, Dr. Willmar Schwabe GmbH and Servier. R. Lanzenberger received travel grants and/or conference speaker honoraria from AstraZeneca, Lundbeck A/S, Dr. Willmar Schwabe GmbH, AOP Orphan Pharmaceuticals AG, Janssen-Cilag Pharma GmbH, and Roche Austria GmbH. T. Vanicek received travel grants and compensation for workshop participation from Pfizer and Eli Lilly and speaker honoraria from Eli Lilly. C. Kraus has received travel grants from Roche Austria GmbH and AOP Orphan Pharmaceuticals AG. M. Willeit received speaker honoraria from Janssen-Cilag Pharma GmbH. A. Weidenauer, T. Khanaqa, M. Stamenkovic, and M. Willeit declare that they have no competing interests.
: This article does not contain any studies with human participants or animals performed by any of the authors. Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.